What is ipamorelin?
Ipamorelin mimics ghrelin at the growth hormone secretagogue receptor — a selective nudge that asks the pituitary for a growth-hormone pulse without meaningfully raising cortisol or appetite. That selectivity is why it's so often studied in combination with CJC-1295 or tesamorelin.
These articles explain the mechanism, the combinations, and the evidence in plain language. Like everything Promise offers, it's prescription-only, and a licensed provider makes the call. If you're weighing it against sermorelin or tesamorelin, the comparison articles are the place to start.
29 articles on this topic
-
CJC-1295 Ipamorelin News: October 2026
The quarter brought a new WADA list, online-product notices and an evidence review. The two molecules still have different FDA records and limited human outcome data.
-
IGF-1 Levels by Age: Reading Your Lab Result
IGF-1 levels by age usually decline after early adulthood. Your lab's range puts the number in context; trial increases aren't treatment targets.
-
Who Discovered Ghrelin? Kojima and Kangawa
Masayasu Kojima, Kenji Kangawa and colleagues identified ghrelin in 1999. Earlier peptide and receptor discoveries set up the finding; appetite studies followed.
-
Tesamorelin Fatty Liver Trial: What It Found
A 12-month trial found less liver fat and less worsening of scarring with tesamorelin. Its 61 participants had HIV, a virus that weakens the immune system, which limits what the findings mean for everyone else.
-
CJC-1295 FDA Status: Nominations, Review and Votes
CJC-1295 is not FDA-approved; a compounded prescription is different from an FDA-approved product. Here is what its nominations and votes mean today.
-
Tesamorelin News Update: September 2026
A quiet quarter for the medicine itself: Egrifta's label and its narrow use did not change. The news came from around it, in FDA's letters to online sellers, WADA's 2027 list and three new papers.
-
Sermorelin Clinical Trials: What the Studies Show
The 11-man study is real. Its results are narrower than the sales pitch, and later studies add evidence without settling the big claims.
-
CJC-1295 Ipamorelin Oral: No Human Absorption Data
No human study has shown that a swallowed or sublingual CJC-1295/ipamorelin product delivers either peptide reliably. The key human drug-level studies used injections or infusions, not pills or troches.
-
Where to Inject CJC-1295 Ipamorelin: Site Guide
CJC-1295/ipamorelin is generally given into fatty tissue just under the skin. Common areas include the abdomen, thigh, back of the upper arm, and upper buttock, but the pharmacy label sets the sites for the exact prescription.
-
Is CJC-1295 Ipamorelin Safe? What We Know
Short human studies offer limited reassurance, but the blend itself has not been tested in a published trial and its long-term safety is unknown. A careful answer has to include both facts.
-
When to Take Sermorelin: Why Bedtime Is Common
Bedtime is the usual convention because the body's largest growth-hormone pulse often follows deep sleep. It is a rhythm to work with, not proof that one clock time fits everyone.
-
CJC-1295 Ipamorelin Cost: What the Price Covers
There is no brand-name version of this blend, so there is no list price to compare against. What you are really choosing between is a prescription with a clinician attached and a vial with nobody attached.
-
Peptide Research 2026: What Three Reviews Found
Three review papers landed within a few weeks of each other this summer. They agree the animal work is real, the human evidence is thin, and that gap is the thing worth understanding.
-
CJC-1295 Ipamorelin for Muscle Growth: No Trial
These peptides can raise signals along the growth hormone pathway, but no human trial has shown that the pair builds muscle or increases strength. The honest case is a plausible mechanism, not a bodybuilding result.
-
CJC-1295 Ipamorelin for Women: Evidence and Limits
CJC-1295 with ipamorelin may stimulate the growth-hormone axis, but no clinical trial has tested the combination specifically in women. Perimenopause, estrogen route and the limits of body-composition and sleep evidence all matter to the prescribing decision.
-
Does CJC-1295 Ipamorelin Work? Evidence Review
The combination has no clinical trial of its own. Separate studies show that CJC-1295 and ipamorelin can raise growth hormone signals, but they do not establish predictable sleep, recovery, muscle, or fat-loss results from the blend.
-
Tesamorelin vs CJC-1295: Evidence and Differences
Both peptides signal through the GHRH receptor, but their structures, duration and human evidence differ sharply. The clearest distinction is phase 3 visceral-fat data for tesamorelin versus biomarker studies for CJC-1295.
-
Peptides vs Steroids: What Makes Them Different?
Peptides and anabolic steroids are different molecules with different targets, evidence, risks, and legal status. A peptide is not simply a steroid under a newer name.
-
Tesamorelin vs Ipamorelin: What Sets Them Apart
Both peptides signal the pituitary to release growth hormone, but they use different receptors and carry very different levels of human evidence. Tesamorelin has phase 3 trial data; ipamorelin does not.
-
Peptides for Muscle Growth: Evidence and Limits
Prescription GH-axis peptides can change hormone levels and, in selected patients, body composition. Human evidence does not show that they produce hypertrophy or greater strength in healthy trained adults.
Page 1 of 2 · 29 articles